I3: Results from clinical studies

Parasympathetic nervous system is the body’s internal relaxation & self-repair mechanism.
Vagus Nerve is its main component that connects to most organs and mediates signals to rest & heal.
Heart Rate Variability (HRV) is an indicator of Vagus Nerve activity.
Improving parameters of HRV indicate targeted stimulation of the vagus nerve and activation of specific self-repair mechanisms of body & mind.
In clinical trials, one hour sessions of Nurosym favourably altered all three parameters of Heart Rate Variability (HRV), when compared to placebo.

Source: Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Cardiovascular and Translational Research Independent Clinical Study on Nurosym device, published in PLOS ONE

Inflammation throughout the body and brain contributes to diseases development, progression, ageing and mental health problems.
Cytokines are the main biomarkers (measures) of inflammation in the body.
In a randomised controlled trial, inflammatory cytokines were significantly lower in the group that received Nurosym neuromodulation compared to the placebo group at the end of 3 months.

Source: Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Journal of Cardiovascular Pharmacology,
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Nature Reviews Cardiology

Nurosym improves memory on learning tasks in comparison to placebo.
(A) There was a significant benefit of Nurosym neuromodulation compared to placebo across all test questions. (B) This effect was driven by a significant benefit of Nurosym neuromodulation on memory questions.

Source: Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Brain Stimulation

Nurosym paired with training improved performance on speed and decoding learning task measures in comparison to placebo.
Nurosym neuromodulation significantly improved speed on the Automaticity learning task compared to controls. Nurosym neuromodulation also significantly improved percent correct on the Decoding learning task as compared to controls. ∗p < 0.05.

Source: Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Brain Stimulation

There was a highly significant improvement in fatigue scores after treatment (D0 vs. D10, p < 0.0001). Fatigue was measured using the Pichot Fatigue Scale. Participants reported that the improvements in fatigue remained 1 week after stopping the treatment.

Source: Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience

A very significant improvement was observed after 10 treatment sessions. (D0 vs. D10: p < 0.0001) We evaluated our proprietary neuromodulation on those suffering with Long-COVID symptoms such as Fatigue, cognitive problems, Depression, Pain etc.
Treatment starts after baseline measurement at Day 0 (D0), ending on D10, with follow up measurements one week later (D17).

Source: Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience

Nurosym neuromodulation decreased depression symptoms & improved mood in only 5 days of treatment.
The figure shows the evolution of the Beck depression scale scores during treatment (day 0, day 5 and day 10). The individual values and the median are shown.

Source: Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience

Effect of active Nurosym neuromodulation vs sham (placebo) stimulation on the postural change in heart rate [Δ(heart rate)] at 2 months.
The analysis showed that postural tachycardia (without a significant drop in blood pressure) was significantly less in subjects who received Nurosym neuromodulation compared to control (postural increase in heart rate 18±10 bpm vs. 32±14 bpm, respectively, p=0.016).

Source: Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology. Independently evaluated and funded, published in Journal of the American College of Cardiology

Nurosym improves blood circulation in comparison to placebo.
(A) Pseudo color images on dorsum of left hand during (1) baseline, (2) occlusion and (3). Postocclusive reactive hyperemia (PORH) phase. Blue color represents lower, red represents higher perfusion rates. (B, C) Changes in blood perfusion measured over nail bed area, before and after Nurosym neuromodulation (B) and sham (placebo) stimulation (C). Markedly higher perfusion rate was seen after Nurosym neuromodulation.

Source: Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently funded & evaluated, peer reviewed & published in Journal of Cardiovascular Pharmacology